IDEXX Laboratories, Inc. — FY2013 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2013, filed February 18, 2014. IDEXX develops diagnostic products and services for companion-animal veterinary, bioresearch, water, livestock, poultry and dairy markets, plus human point-of-care diagnostics. Reportable segments were Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. The company retrospectively combined its livestock and dairy operations into LPD for segment reporting.
International customers represented approximately 42% of 2013 revenue. CAG remained the dominant business, generating $1.15 billion, or approximately 84% of consolidated revenue.
Key financial metrics
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Revenue | $1,377.1 million | $1,293.3 million | 6.5% |
| Gross profit | $756.1 million | $699.1 million | 8.1% |
| Gross margin | 54.9% | 54.1% | +0.8 percentage points |
| Operating income | $266.8 million | $262.6 million | 1.6% |
| Operating margin | 19.4% | 20.3% | -0.9 percentage points |
| Net income attributable to IDEXX stockholders | $187.8 million | $178.3 million | 5.3% |
| Diluted EPS | $3.48 | $3.17 | 9.8% |
| Net cash from operating activities | $246.0 million | $222.4 million | 10.6% |
| Capital expenditures | $77.6 million | $57.6 million | 34.7% |
The fourth quarter of 2013 produced revenue of $354.1 million, gross profit of $188.7 million, operating income of $61.3 million, net income attributable to IDEXX stockholders of $43.3 million and diluted EPS of $0.82.
Revenue mix included $854.5 million of product revenue and $522.5 million of service revenue. Research and development expense was $88.0 million, or 6.4% of revenue. The effective income tax rate declined to 28.7% from 31.6%, primarily because the U.S. R&D tax credit was retroactively reinstated and extended through 2013, together with a greater proportion of earnings in lower-tax international jurisdictions.
Segment performance and material changes
- CAG: Revenue increased 7.3% to $1,150.2 million, with organic growth of 7.8%. Recurring diagnostic revenue increased 8.7%, driven by reference laboratory services and VetLab consumables. VetLab instruments declined 7.5%, partly because revenue from reagent-rental arrangements is recognized over the contract term rather than at placement.
- Water: Revenue increased 3.9% to $88.0 million, primarily from higher Colilert product volumes in Europe and North America. Operating margin declined to 42.4% from 44.5%.
- LPD: Revenue increased 2.2% on a reported basis to $113.8 million, but organic revenue declined approximately 1%. Lower BSE testing volumes in Europe and lower dairy testing volumes offset growth in certain bovine, poultry and swine products. Operating income declined 32.0% to $14.2 million, and segment gross margin fell to 54.9% from 59.4% because of higher manufacturing costs and unfavorable currency effects.
- Other: Revenue was essentially flat at $25.1 million. OPTI Medical consumables and lower manufacturing costs helped offset lower pharmaceutical product sales.
- Cost structure: Consolidated operating expenses increased 12.1%, faster than revenue, reflecting investment in sales and marketing, information technology, research and development and international expansion. CAG sales-force reorganization and expansion increased expenses but management expected to benefit from broader account coverage and cross-selling.
- Unusual items: IDEXX recorded a $3.9 million loss in general and administrative expense after a freight-payment service provider entered bankruptcy following employee fraud and internal-control failures. The company could not determine whether any recovery would be received.
- Acquisition: IDEXX acquired a Brazilian distributor for approximately $10.8 million in cash, recording $6.5 million of goodwill and $4.8 million of amortizable intangible assets, primarily within LPD.
Cash flow, liquidity and debt
| Balance-sheet metric | December 31, 2013 | December 31, 2012 |
|---|---|---|
| Cash and cash equivalents | $279.1 million | $224.0 million |
| Working capital | $174.4 million | $163.2 million |
| Total assets | $1,230.5 million | $1,103.6 million |
| Revolving credit borrowings | $277.0 million | $212.0 million |
| Long-term debt | $150.4 million | $1.4 million |
| Stockholders’ equity | $518.2 million | $636.3 million |
Cash increased by $55.1 million during 2013. Operating cash flow was $246.0 million, investing cash flow was negative $86.1 million and financing cash flow was negative $102.5 million. The company estimated 2014 capital expenditures of approximately $80 million.
In May 2013, IDEXX replaced its $300 million revolving facility with a $450 million unsecured facility maturing May 8, 2018. At year-end, approximately $172 million remained available, subject to a $1 million letter-of-credit reduction. In December 2013, IDEXX issued $150 million of senior notes: $75 million at 3.94% due 2023 and $75 million at 4.04% due 2025. The company complied with its debt covenants at year-end. Management stated that cash, operating cash flow and available borrowings should fund operations, capital requirements and strategic needs for at least the next twelve months.
Share repurchases were substantial: 3.95 million shares were repurchased for $367.8 million in 2013, compared with 1.47 million shares for $132.3 million in 2012. The company had authorization to repurchase approximately 2.96 million additional shares at year-end and had no intention to pay cash dividends.
Guidance, outlook, risks and contingencies
- Management anticipated 2014 revenue pressure of less than $10 million from lower European bovine-testing volumes due to eradication programs and regulatory changes.
- Management expected interest expense to increase in 2014 because of the December 2013 senior-note issuance.
- Management expected approximately $80 million of 2014 capital expenditures.
- The company remained cautiously optimistic about gradual improvement in U.S. veterinary patient visits and economic conditions, while noting continued challenges in parts of Europe.
- Key risks include intense competition, reliance on distributors and sole- or single-source suppliers, regulatory approval requirements, foreign-currency exposure, economic sensitivity of veterinary spending, changes in testing protocols, cybersecurity and operational disruptions, patent expiration or infringement claims, and the limited scale of the OPTI human point-of-care business.
- Henry Schein represented 9% of 2013 revenue and MWI represented 8%, creating customer and channel concentration. The FTC consent agreement limits IDEXX to exclusive distribution agreements with two of the three largest U.S. distributors and permits MWI to carry competing products.
- Contractual cash obligations totaled $407.1 million, including $217.4 million of debt obligations, $69.2 million of operating leases, $116.6 million of purchase obligations and $3.9 million of minimum royalty payments.
- Unrecognized tax benefits were approximately $6.3 million. Approximately $349.8 million of accumulated non-U.S. subsidiary earnings were considered indefinitely reinvested; the potential tax cost of repatriation was not practicable to determine.
- The company had contingent commitments of up to $5.5 million tied primarily to revenue milestones, and $3.1 million of probable pre-acquisition liabilities related to the Brazilian acquisition. Ordinary-course legal proceedings were not expected by management to have a material effect, although unfavorable outcomes could be material in a particular period.
- No goodwill or intangible-asset impairments were identified for 2013. However, future impairment testing remains sensitive to forecast cash flows, growth rates, discount rates and market conditions.
Investor verification checklist
- Verify whether CAG recurring-revenue growth, installed-base expansion and consumable utilization continued to offset declining instrument placements.
- Reconcile operating-margin trends after the 2013 sales-force investments, the freight-provider loss and higher corporate expenses.
- Monitor LPD revenue and margin recovery, particularly European bovine testing and dairy testing volumes.
- Assess leverage, covenant headroom, refinancing requirements and the effect of variable interest rates on debt service.
- Evaluate the sustainability of cash generation after $367.8 million of share repurchases and planned 2014 capital spending.
- Track foreign-currency sensitivity: management estimated that a 10% strengthening of the U.S. dollar would reduce 2014 operating income by approximately $8 million.
- Review the FTC consent-order restrictions, distributor concentration and any changes in distributor purchasing patterns.
- Confirm the treatment and potential tax consequences of foreign cash and indefinitely reinvested foreign earnings.